Table 1.
Baseline clinical characteristics of the SU2C-MARK cohort
| Patient characteristics (n = 393) | All patients, no. (%) |
|---|---|
| Age (years), median (range) | 64 (29–90) |
| Sex | |
| Male | 182 (46) |
| Female | 207 (53) |
| Smoking status | |
| Never | 46 (12) |
| Former | 283 (72) |
| Current | 60 (15) |
| Smoking pack-years | |
| 0 | 47 (12) |
| 1–10 | 46 (12) |
| 11–20 | 50 (13) |
| 21–40 | 125 (32) |
| >40 | 113 (29) |
| Histology | |
| Adenocarcinoma | 286 (73) |
| Squamous | 77 (20) |
| LCNE | 9 (2) |
| Other | 17 (4) |
| PD-L1 expression | |
| 0% | 56 (14) |
| ≥1% | 168 (43) |
| Prior lines of therapy | |
| 0 | 143 (36) |
| 1 | 150 (38) |
| ≥2 | 96 (24) |
| Therapy | |
| PD-(L)1 only | 317 (81) |
| PD-(L)1 + CTLA4 | 65 (17) |
| PD-(L)1 + chemotherapy | 2 (1) |
| BOR | |
| CR/PR | 142 (36) |
| SD | 110 (28) |
| PD | 132 (33) |
The SU2C-MARK cohort consists of 393 patients with NSCLC treated with immune checkpoint blockade therapy in the advanced setting. BOR to the first line containing a PD-(L)1 agent was recorded.